Development of a New Diagnostic Tool to Assess Oocyte Quality Based on Tachykinin and Kisspeptin Expression Analysis in Human Granulosa and Cumulus Cells
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Infertility
- Sponsor
- IVI Sevilla
- Enrollment
- 236
- Locations
- 2
- Primary Endpoint
- Expression level of neurokinin A (NKA)
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
The purpose of this project is to study the presence of expression differences - at RNA and protein level - of different members of the tachykinin family and kisspeptin and their receptors, between fertile women and infertile patients with different etiologies.
Investigators
Manuel Fernandez-Sanchez
Dr
IVI Sevilla
Eligibility Criteria
Inclusion Criteria
- •Age between 18 and 34 years
- •Normal caryotype
- •Normal psychological test
Exclusion Criteria
- •Presence of hereditary diseases
- •Beta-thalassemia
- •Cystic fibrosis
- •Human immunodeficiency virus (HIV), Hepatitis B virus (HBV), Hepatitis C virus (HCV)
- •Infertility patients
- •Inclusion Criteria:
- •Age between 18 and 45 years
- •One of the following etiologies:
- •Patient with PCOS according to Rotterdam Criteria or
- •Patients with endometriosis stage I-IV or
Outcomes
Primary Outcomes
Expression level of neurokinin A (NKA)
Time Frame: 4 years
Expression analysis at mRNA and protein level using techniques of real time quantitative PCR, immunocytochemistry and western blot
Expression level of hemokinin 1 (HK-1)
Time Frame: 4 years
Expression analysis at mRNA and protein level using techniques of real time quantitative PCR, immunocytochemistry and western blot
Expression level of kisspeptin 1 (KISS1)
Time Frame: 4 years
Expression analysis at mRNA and protein level using techniques of real time quantitative PCR, immunocytochemistry and western blot
Expression level of Substance P (SP)
Time Frame: 4 years
Expression analysis at mRNA (mRNA = messenger ribonucleic acid) and protein level using techniques of real time quantitative PCR (PCR = polymerase chain reaction), immunocytochemistry and western blot
Expression level of neurokinin B (NKB)
Time Frame: 4 years
Expression analysis at mRNA and protein level using techniques of real time quantitative PCR, immunocytochemistry and western blot
Expression level of neurokinin 1 receptor (NK1R)
Time Frame: 4 years
Expression analysis at mRNA and protein level using techniques of real time quantitative PCR, immunocytochemistry and western blot
Expression level of kisspeptin 1 receptor (KISS1R)
Time Frame: 4 years
Expression analysis at mRNA and protein level using techniques of real time quantitative PCR, immunocytochemistry and western blot
Expression of neurokinin 2 receptor (NK2R)
Time Frame: 4 years
Expression analysis at mRNA and protein level using techniques of real time quantitative PCR, immunocytochemistry and western blot
Expression level of neurokinin 3 receptor (NK3R)
Time Frame: 4 years
Expression analysis at mRNA and protein level using techniques of real time quantitative PCR, immunocytochemistry and western blot
Secondary Outcomes
- Years of infertility(4 years)
- Fertilization rate(4 years)
- Embryo quality(4 years)
- Daily and total dose of FSH (FSH = follicle stimulating hormone)(4 years)
- Patient or donor age(4 years)
- Estradiol level (day of ovulation induction)(4 years)
- Patient or donor body mass index(4 years)
- Progesterone level (day of ovulation induction)(4 years)
- Number of oocytes retrieved in the ovarian puncture(4 years)
- Daily and total dose of HMG (HMG = human menopausal gonadotropin)(4 years)
- Number of mature oocytes (metaphase II) obtained in the ovarian puncture(4 years)
- Type of ovulation induction(4 years)